IP Library Granted Patent US 8,759,492
Granted Patent B2
US 8,759,492 · App. 13/588,957 · Granted Jun 24, 2014

Engineered red-shifted channelrhodopsin variants

Inventors: John Yu-luen Lin (Del Mar, CA); Roger Y. Tsien (La Jolla, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,492
App. No.
13/588,957
Granted
Jun 24, 2014
Kind
B2
Abstract

The invention provides engineered red-shifted channelrhodopsin variants. In some embodiments, the channelrhodopsin variants are characterized by improved membrane trafficking, expression, and/or unique spectral and kinetic properties.

Claims (17)

1. A polypeptide comprising a channelrhodopsin-1 (ChR1) domain, a Volvox carteri channelrhodopsin-1 (VChR1) domain and a Volvox carteri channelrhodopsin-2 (VChR2) domain, wherein said polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1.

2. The polypeptide of claim 1 , wherein the polypeptide has the structure:

X 1 -X 2 -X 3 -X 4

wherein X 1 is a ChR1 domain,

X 2 is a first VChR1 domain,

X 3 is a VChR2 domain and

X 4 is a second VChR1 domain.

3. The polypeptide of claim 2 , wherein one or more of the domains X 1 , X 2 , X 3 , and X 4 comprises 1, 2, 3, 4, or 5 amino acid substitutions relative to a corresponding wild-type domain.

4. The polypeptide of claim 3 , wherein the amino acid substition is at one or more positions selected from 163, 171, 174 and 266.

5. The polypeptide of claim 3 , comprising one or more amino acid substitutions selected from Glu163Thr, Leu171Ile, Leu171Val, His174Arg, and Phe266Tyr.

6. The polypeptide of claim 1 further comprising a fluorescent polypeptide.

7. The polypeptide according to claim 1 , comprising an L171I amino acid substitution.

8. The polypeptide of claim 1 , comprising the amino acid sequence of SEQ ID NO:1.

9. The polypeptide of claim 1 , comprising the amino acid sequence of SEQ ID NO:4.

10. The polypeptide of claim 1 , wherein the polypeptide provides a photocurrent of at least 10 pA/pF upon photostimulation with light having a wavelength of at least 600 nm in HEK293 cells.

11. The polypeptide of claim 1 , wherein the ratio of membrane to cytosol localization of the polypeptide is at least 1.0, when expressed in an HEK293 cell.

12. The polypeptide of claim 1 , further comprising a fluorescent protein fused to the C-tertninus.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jun 7, 2016
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038903/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2012
From: LIN, JOHN YU-LUEN; TSIEN, ROGER Y.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 029228/0336 →
CONFIRMATORY LICENSE Recorded Sep 27, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029045/0472 →
Continuity (2)
Provisional Application 61524618 · Aug 17, 2011
Related Publication 20130066402A1 · Mar 14, 2013